Scholarlink

<p>Immunotherapy has led to a paradigm shift in the treatment of various tumors. However, the results obtained sometimes show heterogeneous and inconsistent responses despite the presence of biomarkers such as PD-L1. Recent studies suggest that the efficacy of immunotherapy may vary based on sex, although the findings remain controversial. The aim of this comprehensive review is to evaluate the available evidence and the biological mechanisms that could explain these differences. Some recent meta-analyses have suggested a greater overall survival benefit for males. Theoretical models, supported by in vivo studies in different animal species, are currently focused on the implications of the tumor microenvironment, hormonal factors in the antitumor activity of the immune system and their correlation with the patient’s sex. Other chromosomal sex-specific alterations could be influenced by epigenetic changes affecting genetic material. Prospective studies are needed to further investigate the uncertain relationship between sex and immunotherapy in humans.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A comprehensive review of sex differences in the clinical outcomes to immunotherapy on solid tumors

  • 期刊论文

  • 发表日期：

    2025年12月5日

查看全文
  • Juan Carlos Redondo-González,
  • Luis Posado-Domínguez,
  • Laura Corvo-Félix,
  • Lorena Bellido Hernández,
  • Iñigo San Miguel-Arregui,
  • Emilio Fonseca-Sánchez,
  • Alejandro Olivares-Hernández,
  • Edel del Barco-Morillo

摘要

Immunotherapy has led to a paradigm shift in the treatment of various tumors. However, the results obtained sometimes show heterogeneous and inconsistent responses despite the presence of biomarkers such as PD-L1. Recent studies suggest that the efficacy of immunotherapy may vary based on sex, although the findings remain controversial. The aim of this comprehensive review is to evaluate the available evidence and the biological mechanisms that could explain these differences. Some recent meta-analyses have suggested a greater overall survival benefit for males. Theoretical models, supported by in vivo studies in different animal species, are currently focused on the implications of the tumor microenvironment, hormonal factors in the antitumor activity of the immune system and their correlation with the patient’s sex. Other chromosomal sex-specific alterations could be influenced by epigenetic changes affecting genetic material. Prospective studies are needed to further investigate the uncertain relationship between sex and immunotherapy in humans.